Marginal zone-related neoplasms of splenic and nodal origin

Luca Arcaini, Marco Paulli, Emanuela Boveri, Umberto Magrini, Mario Lazzarino

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background. The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx. Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells). These two entities are well characterized histologically, but specific biological markers are lacking. Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon. No prospective studies have been conducted so far. Information sources. Clinical and pathologic data were reviewed by searches of the published medical literature, including searches in PubMed®, important printed publications, and abstracts presented at recent hematology and pathology meetings. State of the art. Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course. A subset of patients, however, presents with more aggressive disease and have a shorter survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma. The optimal treatment has not yet been identified. Retrospective series, however, show that splenectomy is a good option if symptoms from the presence of spleen enlargement or cytopenias need to be treated. The utility of purine analogs and of anti-CD20 immunotherapy needs to be clarified in prospective trials. Perspectives. Clinicians and pathologists should cooperate to define stringent diagnostic criteria for these indolent disorders. The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.

Original languageEnglish
Pages (from-to)80-93
Number of pages14
JournalHaematologica
Volume88
Issue number1
Publication statusPublished - Feb 1 2003

Fingerprint

Splenic Neoplasms
Lymphoma
Marginal Zone B-Cell Lymphoma
B-Lymphocytes
Hepacivirus
Lymphocytes
Biological Factors
Lymphoid Tissue
Splenectomy
Hematology
Virus Diseases
Therapeutics
PubMed
Non-Hodgkin's Lymphoma
Immunotherapy
Interferons
Publications
Spleen
Biomarkers
Clinical Trials

Keywords

  • Low-grade non-Hodgkin's lymphoma
  • Marginal zone
  • Nodal marginal zone lymphoma
  • Splenic marginal zone lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Marginal zone-related neoplasms of splenic and nodal origin. / Arcaini, Luca; Paulli, Marco; Boveri, Emanuela; Magrini, Umberto; Lazzarino, Mario.

In: Haematologica, Vol. 88, No. 1, 01.02.2003, p. 80-93.

Research output: Contribution to journalArticle

Arcaini, Luca ; Paulli, Marco ; Boveri, Emanuela ; Magrini, Umberto ; Lazzarino, Mario. / Marginal zone-related neoplasms of splenic and nodal origin. In: Haematologica. 2003 ; Vol. 88, No. 1. pp. 80-93.
@article{8a94670adce943b0ac062d7279d9bbcb,
title = "Marginal zone-related neoplasms of splenic and nodal origin",
abstract = "Background. The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx. Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells). These two entities are well characterized histologically, but specific biological markers are lacking. Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon. No prospective studies have been conducted so far. Information sources. Clinical and pathologic data were reviewed by searches of the published medical literature, including searches in PubMed{\circledR}, important printed publications, and abstracts presented at recent hematology and pathology meetings. State of the art. Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course. A subset of patients, however, presents with more aggressive disease and have a shorter survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma. The optimal treatment has not yet been identified. Retrospective series, however, show that splenectomy is a good option if symptoms from the presence of spleen enlargement or cytopenias need to be treated. The utility of purine analogs and of anti-CD20 immunotherapy needs to be clarified in prospective trials. Perspectives. Clinicians and pathologists should cooperate to define stringent diagnostic criteria for these indolent disorders. The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.",
keywords = "Low-grade non-Hodgkin's lymphoma, Marginal zone, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma",
author = "Luca Arcaini and Marco Paulli and Emanuela Boveri and Umberto Magrini and Mario Lazzarino",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "88",
pages = "80--93",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Marginal zone-related neoplasms of splenic and nodal origin

AU - Arcaini, Luca

AU - Paulli, Marco

AU - Boveri, Emanuela

AU - Magrini, Umberto

AU - Lazzarino, Mario

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Background. The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx. Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells). These two entities are well characterized histologically, but specific biological markers are lacking. Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon. No prospective studies have been conducted so far. Information sources. Clinical and pathologic data were reviewed by searches of the published medical literature, including searches in PubMed®, important printed publications, and abstracts presented at recent hematology and pathology meetings. State of the art. Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course. A subset of patients, however, presents with more aggressive disease and have a shorter survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma. The optimal treatment has not yet been identified. Retrospective series, however, show that splenectomy is a good option if symptoms from the presence of spleen enlargement or cytopenias need to be treated. The utility of purine analogs and of anti-CD20 immunotherapy needs to be clarified in prospective trials. Perspectives. Clinicians and pathologists should cooperate to define stringent diagnostic criteria for these indolent disorders. The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.

AB - Background. The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx. Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells). These two entities are well characterized histologically, but specific biological markers are lacking. Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon. No prospective studies have been conducted so far. Information sources. Clinical and pathologic data were reviewed by searches of the published medical literature, including searches in PubMed®, important printed publications, and abstracts presented at recent hematology and pathology meetings. State of the art. Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course. A subset of patients, however, presents with more aggressive disease and have a shorter survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma. The optimal treatment has not yet been identified. Retrospective series, however, show that splenectomy is a good option if symptoms from the presence of spleen enlargement or cytopenias need to be treated. The utility of purine analogs and of anti-CD20 immunotherapy needs to be clarified in prospective trials. Perspectives. Clinicians and pathologists should cooperate to define stringent diagnostic criteria for these indolent disorders. The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.

KW - Low-grade non-Hodgkin's lymphoma

KW - Marginal zone

KW - Nodal marginal zone lymphoma

KW - Splenic marginal zone lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0037309491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037309491&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 80

EP - 93

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -